CA2450315A1 - Ligands des recepteurs de dopamine et procedes therapeutiques correspondants - Google Patents

Ligands des recepteurs de dopamine et procedes therapeutiques correspondants Download PDF

Info

Publication number
CA2450315A1
CA2450315A1 CA002450315A CA2450315A CA2450315A1 CA 2450315 A1 CA2450315 A1 CA 2450315A1 CA 002450315 A CA002450315 A CA 002450315A CA 2450315 A CA2450315 A CA 2450315A CA 2450315 A1 CA2450315 A1 CA 2450315A1
Authority
CA
Canada
Prior art keywords
receptor
compound
dopamine
subject
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002450315A
Other languages
English (en)
Inventor
Shaomeng Wang
Judith Varady
Xihan Wu
Min JI
Ke Ding
Beth Levant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2450315A1 publication Critical patent/CA2450315A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés désignés comme ligands (<i>e</i>.<i>g</i>., agonistes, antagonistes et agonistes partiels) pour les récepteurs de dopamine (<i>e</i>.<i>g</i>., D¿1?, D¿2?, D¿3?, D¿4? et D¿5?) et notamment les récepteurs de dopamine D¿1?, D¿2? et D¿3?. La présente invention concerne aussi des procédés de conception rationnelle de ces composants et des procédés thérapeutiques de leur utilisation.
CA002450315A 2001-06-13 2002-06-13 Ligands des recepteurs de dopamine et procedes therapeutiques correspondants Abandoned CA2450315A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29744501P 2001-06-13 2001-06-13
US60/297,445 2001-06-13
PCT/US2002/018914 WO2002100350A2 (fr) 2001-06-13 2002-06-13 Ligands des recepteurs de dopamine et procedes therapeutiques correspondants
USUNKNOWN 2011-05-19

Publications (1)

Publication Number Publication Date
CA2450315A1 true CA2450315A1 (fr) 2002-12-19

Family

ID=23146337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002450315A Abandoned CA2450315A1 (fr) 2001-06-13 2002-06-13 Ligands des recepteurs de dopamine et procedes therapeutiques correspondants

Country Status (3)

Country Link
EP (1) EP1406631A4 (fr)
CA (1) CA2450315A1 (fr)
WO (1) WO2002100350A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104997743A (zh) * 2008-07-16 2015-10-28 吉瑞工厂 包含多巴胺受体配体的药物制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226459A1 (de) * 2002-06-13 2004-01-08 Neurobiotec Gmbh Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms
EP1588704A1 (fr) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
WO2005110414A2 (fr) 2004-05-07 2005-11-24 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2423668T3 (es) 2009-05-22 2013-09-23 Abbvie Inc. Moduladores de receptores 5-HT y métodos de uso de los mismos
CN103002735B (zh) 2010-05-21 2015-05-20 Abbvie公司 5-ht受体的调节剂和其使用方法
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
WO2016203347A1 (fr) 2015-06-17 2016-12-22 Pfizer Inc. Composés tricycliques et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
ES2950507T3 (es) * 2015-08-19 2023-10-10 Univ East Carolina Tratamiento y gestión del aumento del síndrome de piernas inquietas
CN105418605B (zh) * 2015-11-23 2017-12-22 东南大学 一种改进的含氮三环类多巴胺d3受体配体的制备方法
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH496720A (de) * 1966-10-05 1970-09-30 Ciba Geigy Verfahren zur Herstellung neuer Pyrazino(1,2-a)-chinoline
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
BR9406128A (pt) * 1993-03-01 1996-02-27 Merck Sharp & Dohme Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
DE69530988T2 (de) * 1994-08-05 2003-12-04 Pfizer Benzimidazolderivate mit dopaminerger wirkung
WO1996023789A1 (fr) * 1995-02-03 1996-08-08 Sankyo Company, Limited Derives d'hexahydropyrazinoquinoline
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104997743A (zh) * 2008-07-16 2015-10-28 吉瑞工厂 包含多巴胺受体配体的药物制剂

Also Published As

Publication number Publication date
EP1406631A2 (fr) 2004-04-14
WO2002100350A2 (fr) 2002-12-19
WO2002100350A3 (fr) 2003-05-22
EP1406631A4 (fr) 2005-03-23

Similar Documents

Publication Publication Date Title
Hwa et al. Identification of Critical Determinants of α1-Adrenergic Receptor Subtype Selective Agonist Binding (∗)
Dubost et al. Synthesis and structure–affinity relationships of selective high-affinity 5-HT4 receptor antagonists: application to the design of new potential single photon emission computed tomography tracers
Song et al. The Difference between the CB1 and CB2Cannabinoid Receptors at Position 5.46 Is Crucial for the Selectivity of WIN55212-2 for CB2
CA2450315A1 (fr) Ligands des recepteurs de dopamine et procedes therapeutiques correspondants
TW530043B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
Andersen et al. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters
Männel et al. Hydroxy-substituted heteroarylpiperazines: novel scaffolds for β-arrestin-biased D2R agonists
JP2001324496A (ja) 選択的セロトニン再取り込み抑制剤のｃｙｐ２ｄ６阻害能を同定するためのファルマコフォア・モデル
Zheng et al. Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists
US9422229B2 (en) Therapeutic compounds
Bonifazi et al. Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism
Roman et al. Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis
Bonifazi et al. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl) propyl]-1, 2, 3, 4-tetrahydroquinolin-2-one (77-LH-28-1)
Shen et al. D2 dopamine receptor G protein-biased partial agonists based on cariprazine
Wang et al. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods
Bedini et al. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives
Yanai et al. Identification and molecular docking studies for novel inverse agonists of SREB, super conserved receptor expressed in brain
Martini et al. Defining Structure–Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists
Perry et al. Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT1A and 5-HT7 G protein-coupled receptor affinity, 3D-QSAR and molecular modeling
TW201902481A (zh) 用於治療精神分裂症之氘化１－哌－３－苯基－二氫茚
Pang et al. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays
Del Bello et al. 1, 4-Dioxane, a suitable scaffold for the development of novel M3 muscarinic receptor antagonists
Eglen et al. Selective inactivation of muscarinic receptor subtypes
Price et al. Subtle differences among 5-HT3AC, 5-HT3AD, and 5-HT3AE receptors are revealed by partial agonists
Chen et al. Synthesis and structure–activity relationships of tool compounds based on WAY163909, a 5-HT2C receptor agonist

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead